MGMT-UNMETHYLATED GLIOBLASTOMA
Clinical trials for MGMT-UNMETHYLATED GLIOBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new MGMT-UNMETHYLATED GLIOBLASTOMA trials appear
Sign up with your email to follow new studies for MGMT-UNMETHYLATED GLIOBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on deadly brain tumors in first human trial
Disease control Recruiting nowThis early-stage trial tests a new treatment for glioblastoma, an aggressive brain cancer. Researchers take a patient's own immune cells, modify them in the lab to better recognize and attack the tumor, and then infuse them back. The study involves 20 adults whose tumors have a s…
Matched conditions: MGMT-UNMETHYLATED GLIOBLASTOMA
Phase: PHASE1 • Sponsor: Hideho Okada, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for brain cancer: experimental virus therapy targets aggressive tumors
Disease control Recruiting nowThis study tests whether adding two experimental drugs, DB107-RRV and DB107-FC, to standard treatment (radiation and chemotherapy) can help people with newly diagnosed high grade glioma, a fast-growing brain cancer. About 70 adults aged 18-75 will receive the drugs during and aft…
Matched conditions: MGMT-UNMETHYLATED GLIOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo takes on deadly brain tumor
Disease control Recruiting nowThis trial tests whether adding the drug WP1066 to standard radiation therapy can help people with newly diagnosed glioblastoma, a fast-growing brain cancer. WP1066 targets a protein called STAT3 that helps tumors grow and hide from the immune system. The study will enroll 39 pat…
Matched conditions: MGMT-UNMETHYLATED GLIOBLASTOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could a new combo therapy extend life in aggressive brain cancer?
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard treatment (radiation and temozolomide) helps people with newly diagnosed glioblastoma live longer. About 190 adults will be randomly assigned to receive either the standard treatment alone or standard treatment plus…
Matched conditions: MGMT-UNMETHYLATED GLIOBLASTOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC